Explore /
Poster
/ Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.

Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.

Authors

Juan Francisco Rodriguez-Moreno

HM Hospitales-Centro Integral Oncológico Clara Campal, Madrid, Spain

Juan Francisco Rodriguez-Moreno , Guillermo de Velasco , Inmaculada Bravo Fernandez , Carlos Alvarez-Fernandez , Ricardo Fernandez , Sergio Vazquez-Estevez , Juan Antonio Virizuela , Pablo Gajate , Albert Font , Nuria Lainez , Arantzazu Martínez Barquín García , Sergio Ruiz-Llorente , Luis Beltran , Cristina Rodríguez-Antona , Pedro Berraondo , Jesús García-Donas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Translational Research

Clinical Trial Registration Number

NCT03534492

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 542)

Abstract #

542

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2019 Genitourinary Cancers Symposium